Imagine a loved one battling Alzheimer’s, only to have their struggle compounded by a hidden enemy: agitation. This often-overlooked symptom affects nearly half of Alzheimer’s patients, yet it remains shrouded in misunderstanding and stigma. Pharmaceutical giants Lundbeck and Otsuka, makers of the Alzheimer’s agitation treatment Rexulti, are shedding light on this ‘blind spot’ through a groundbreaking survey. But here’s where it gets eye-opening: the survey, conducted by the Alliance for Aging Research (AAR) and involving 1,000 U.S. adults and 1,000 caregivers, exposes startling gaps in awareness and care.
The report, titled The Agitation Blindspot in Alzheimer’s Care, reveals that 40% of adults fail to associate agitation—characterized by restlessness, disinhibition, and aggression—with Alzheimer’s. Even more concerning, only a third of caregivers link physical aggression or disinhibition to the disease. And this is the part most people miss: nearly 75% of caregivers mistakenly believe agitation can be managed like memory loss, when in reality, it requires distinct diagnosis and treatment. This misconception not only hinders effective care but also exacerbates the emotional toll on caregivers, with over 90% feeling overwhelmed, isolated, and emotionally drained. More than 30% admit hesitating to discuss agitation symptoms with doctors due to fear, guilt, or stigma.
But here’s the controversial part: Could the pharmaceutical industry’s focus on treatments like Rexulti inadvertently contribute to this lack of awareness? While Lundbeck and Otsuka’s drug has seen remarkable growth—with global sales nearing $729 million in 2025 and a 660% surge in U.S. prescriptions since FDA approval—the survey underscores that medication alone isn’t enough. Education and support systems are equally critical. Sue Peschin, AAR’s CEO, emphasizes the urgent need to empower caregivers and healthcare professionals to recognize and address agitation effectively.
This raises a thought-provoking question: Are we doing enough to bridge the gap between medical advancements and public understanding? What do you think? Share your thoughts in the comments below. The journey to better Alzheimer’s care starts with conversations like these.
